



ASX / Media Release
7 January 2016

Share Option Vesting Conditions Met

SYDNEY, 7 January, 2016: OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) announced today that pursuant to ASX Listing Rule 3.10A the final 3,000,000 options which were subject to voluntary escrow entered into by Mr. Martin Rogers as originally approved by shareholders on 23 May 2013, will be released from escrow on 21 January 2016.

Unlisted Options	Exercise Price	Expiry Date	# of options	Vesting Conditions	Released from Escrow
Class D	\$0.05	23 May 2017	3,000,000	Company shares traded at a volume weighted average price of \$0.20 or above on the ASX for 10 consecutive days	21 January 2016

ENDS

Contact:

Mr Daniel Kenny
Chief Executive Officer and Managing Director
E: daniel.kenny@oncosil.com.au
T: +61 2 9223 3344

James Moses
Mandate Corporate
E: james@mandatecorporate.com.au
M: +61 420 991 574
T: +61 2 8211 0612

About OncoSil Medical Ltd

OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian Lifesciences company with the aim to provide new technologies for safer medical radiation treatments. OncoSil Medical's lead product is OncoSil™ with the first target indication being pancreatic cancer. OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumours outside of pancreatic cancer. FDA and CE Mark approval for the treatment of pancreatic cancer are the immediate focus of OncoSil Medical.

Pancreatic Cancer

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$1b.

Hepatocellular carcinoma liver cancer

Hepatocellular carcinoma (HCC) is the 6th most common cancer in the world with 782,000 new cases diagnosed in 2012. Its poor prognosis makes HCC the third leading cause of cancer related mortality responsible for approximately 600,000 deaths annually. Hepatocellular carcinoma can sometimes be cured by surgery or transplantation. However the vast majority of patients with HCC have disease which is too advanced for surgical intervention and as a consequence, survival ranges from a few months to two or more years depending on the liver function at diagnosis and the extent of tumour invasion. The size of the hepatocellular cancer (HCC) market is expected to triple in size by 2019 to \$1.4b.

References

- Global Industry Analysts 2010
- BIOSDP-201. A single dose, single centre open label Phase I/II Safety Study in Hepatocarcinoma
- Venook et al. The incidence of Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. The Oncologist; 15 Supplement 5-13
- <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/pancreatic-cancer-statistics>
- <http://www.datamonitorhealthcare.com/hepatocellular-cancer-market-to-treble-in-size-by-2019>
- <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/liver-cancer-statistics>